Publicly-traded company Juno Therapeutics, Inc. (NASDAQ:JUNO) had a closing price of $56.05 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $55.54, this means that the stock is overpriced by -0.918%. In the past 52 weeks the company’s stock price has moved within the range of $17.52 to $61.59.

This particular stock’s 5-day moving average is 55.80, its 20-day moving average is 49.43 and its 100-day moving average is 37.99. Juno Therapeutics, Inc. (JUNO) currently has 114170 shares outstanding, which means that its market capitalization is $6.05B.

What Does Wall Street Say about Company?

When considering a new stock purchase, a lot of investors find out how Wall Street analysts feel about the company before they buy in. You can do this by looking for the average analyst rating on the company’s stock. At the moment, the average analyst rating for JUNO is Moderate Buy. Out of 11 total analysts who were surveyed, 1 rated it a Moderate Buy, 3 rated it hold, and 7 rated it a Strong Buy.

Three months ago, on the other hand, the average analyst rating for Juno Therapeutics, Inc. (JUNO) was a Hold – from a survey of 9 analysts. Of the analysts who provided ratings, 5 rated the company a Hold, 1 rated it a Strong Sell, and 3 rated it a Strong Buy.

Understanding Profitability at Juno Therapeutics, Inc. (JUNO)

Having a look at a company’s recent Earnings per Share (EPS) performance is a useful way of understanding its profitability. In the most recent financial results released by Juno Therapeutics, Inc., for the quarter ending on 2017-09-30, the company posted EPS of -1.12. The average estimate of Wall Street analysts had projected -0.84.

Wall Street analysts, on average, are forecasting the company’s EPS to be -1.01, compared to -0.65 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 12 analysts is 19.06 million – compared to $21.15 million posted in the year-ago period.